ATH434 protects brain cells and improves motor function in Parkinsonian disorder

Oral presentation at the American Academy of Neurology

ATH434 protects brain cells and improves motor function in Parkinsonian disorder

MELBOURNE, Australia , April 21, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced an oral presentation of expanded animal data to support the commercialisation of its lead compound ATH434 in clinical development for the...

Read more: ATH434 protects brain cells and improves motor function in Parkinsonian disorder

More Articles …

  1. Deliverect raises $65 million as it surpasses 30 million orders processed in the last year, equating to more than $1bn estimated order value
  2. New Study: Australia and New Zealand leading APAC in entrepreneurial spirit, optimism and confidence
  3. PageUp named one of Australia's Best Places to Work in 2021
  4. New Report Reveals That Australian Financial Websites Are Falling Behind In Industry & Accessibility Compliance
  5. Clinical Trial Industry Veteran Paul Malan Joins Bioforum as Vice President of Biostatistics
  6. Mathletes get ready - World Maths Day is back
  7. Lendary launches high yield margin-lending algorithm for crypto trading in Asia
  8. Anywhere365® Launches Attendant Console for Microsoft Teams
  9. iMDsoft announces Dedalus as their Channel Partner in Australia and New Zealand for MetaVision Clinical Information System, iMDsoft's best of class product suite
  10. Booking.com research explores Australian traveller optimism